Startup Nursery Q1 2022 Insight
May 03, 2022
Despite an initial surge in COVID-19 cases and deaths in the beginning of the year, it is reassuring to see numbers for both decrease to more manageable levels. With the majority of the world vaccinated (upward of 64%), we see a loosening of COVID-19 restrictions across the board.
Ikove is a venture development company founded to pursue early-stage investments with an emphasis on technology commercialization. Through its proprietary Startup Nursery, in partnership with multiple U.S. research institutions, Ikove identifies and validates developing high-impact technologies, providing capital and commercialization resources to bridge the gap between R&D and VC funded rounds.
We go to the source
Ikove pursues technologies that have been developed and reinforced by significant investments in R&D at leading research institutions. Technologies are vetted through our Startup Nursery, and if they survive, we recruit CEOs and operators to be part of the founding cap table of the companies.
We Focus Where Few are Looking
We are headquartered in the Midwest, where we have access to world-class technologies, infrastructure and teams at a fraction of the cost of the East and West Coasts. Our CEOs can relocate the companies where they see a strategic fit but still have the benefits of lower costs and valuation arbitrage as the operating businesses settles in places like San Francisco, New York City or Hong Kong.
We are Founders
Ikove is heavily involved in the launch and operations of the business alongside each company’s management team. We focus on deep tech businesses instead of investing in or developing the latest trending app; we prefer to focus on disrupting industries that are backed by strong and significant IP.
We Invest in DeepTech
We invest in technologies that solves big problems with significant market potential and are backed by strong intellectual property and knowhow.
Build to Sell
We build our companies to become fast-growing, profitable businesses that can go all the way to IPOs; but given current exit dynamics, we position our portfolio companies in a way that they can be acquisition targets. We develop our companies with a clear “build-to-sell” focus.
Subscribe to Ikove Insights
Enter your email address to subscribe to Ikove Insights delivered right to your inbox.